BioNTech, Autolus strike wide-ranging licensing and manufacturing deal for CAR-T therapies
08 Feb 2024
License out/inCell TherapyImmunotherapyClinical Study
BioNTech is enlisting CAR-T biotech Autolus Therapeutics on a partnership aimed at pushing both of their CAR-T programs toward commercialization, with an eye on its new partner’s programs as well as manufacturing capabilities.
As part of the wide-ranging agreement, BioNTech will purchase $200 million of Autolus’ shares in a private placement, plus dish out a cash payment of $50 million.
In exchange, BioNTech will receive up to mid-single digit royalty on net sales of Autolus’ lead CD19 therapy, obe-cel, which is now under review at the FDA for relapsed/refractory adult B cell acute lymphoblastic leukemia. It will also have an option to get a profit share on Autolus’ other CAR-T therapies, AUTO1/22 and AUTO6NG, in any cancer type, if it co-supports development and commercialization. Autolus will be eligible to receive an option exercise fee, milestone payments and co-funding of development expenses.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Targets
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.